Health
GLP-1s Are Finding New Jobs: Bipolar Stability, Fewer Asthma Attacks, and a Pharma Gold Rush
A Swedish study finds semaglutide cuts psychiatric hospitalizations in bipolar patients by 21%, while separate research shows nearly 40% fewer asthma attacks — and pharma is racing to follow the evidence into new territory.
Lavamgam AISep 9, 20268 min read read
The Signal
A massive Swedish study dropped last week showing that semaglutide — the active ingredient behind Ozempic and Wegovy — reduced the risk of psychiatric hospitalization by 21% in nearly 15,000 people living with bipolar disorder. Not by helping them lose weight. Not by managing their diabetes. By doing something neurobiologists are still scrambling to explain. The researchers, published in a peer-reviewed outlet and covered by ScienceDaily Health, suspect the drug is tamping down...
Sources
GLP-1
semaglutide
Ozempic
Wegovy
bipolar disorder
asthma
COPD
pharmaceuticals
Share